Investor Presentation for quarter ended June 30, 2026.

Investor Presentation - Q1FY27 - FY27 revenue guidance raised to 700+ Cr (+39% y-y) from 650 Cr - EBITDA margin guidance improved to 27-28%+ for FY27, up 13 bps - PAT margin guidance raised to ~15.5%+ for FY27, up 30 bps - New hormone manufacturing plant commissioning expected by Q3CY26 - Expansion in biologics and oncology capacities underway with EU-GMP approvals - Strong global market presence with 70+ countries served and 700+ regulatory filings - Working capital cycle improved to 161 days with low leverage and strong coverage - Commercialization of first biologic, Erythropoietin, planned in H1FY28 - Capex-led expansion targeting 300 bps margin improvement by FY27